We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-6.57%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$992B
AUM Growth
-$120B
Cap. Flow
-$16.9B
Cap. Flow %
-1.7%
Top 10 Hldgs %
27.94%
Holding
3,085
New
108
Increased
1,637
Reduced
1,059
Closed
107

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$4.45B
2
JPM icon
JPMorgan Chase
JPM
+$2.22B
3
TEAM icon
Atlassian
TEAM
+$2.08B
4
NVDA icon
NVIDIA
NVDA
+$1.81B
5
AAPL icon
Apple
AAPL
+$1.67B

Sector Composition

Rank Sector Weight
1 Technology 26.79%
2 Healthcare 17.19%
3 Consumer Discretionary 15.16%
4 Financials 10.74%
5 Communication Services 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AFACW
2951
DELISTED
Arena Fortify Acquisition Corp. Warrant
AFACW
$9K ﹤0.01%
+37,500
New +$14.7K
TRVN
2952
DELISTED
Trevena, Inc.
TRVN
$8K ﹤0.01%
23
+7
+44% +$2.21K
PRPC.WS
2953
DELISTED
CC Neuberger Principal Holdings III Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
PRPC.WS
$8K ﹤0.01%
12,125
MLAIW
2954
DELISTED
McLaren Technology Acquisition Corp. Warrant
MLAIW
$8K ﹤0.01%
+37,750
New +$11.6K
NBEV
2955
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$7K ﹤0.01%
+12,443
New +$8.9K
LITS
2956
Lite Strategy Inc
LITS
$30.4M
$6K ﹤0.01%
+516
New +$20.3K
EUCRW
2957
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$4K ﹤0.01%
22,697
STAB
2958
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
$4K ﹤0.01%
+11,700
New +$12.5K
VELOW
2959
DELISTED
Velocity Acquisition Corp. Warrant
VELOW
$4K ﹤0.01%
11,329
NBIS
2960
Nebius Group N.V.
NBIS
$72.3B
$1K ﹤0.01%
5,534,087
+2,873,592
+108% +$136M
AA icon
2961
PUT
Alcoa
AA
$13.4B
-35,500
Closed -$2.01M
AHRT
2962
AH Realty Trust
AHRT
$507M
-72,708
Closed -$1.11M
ANIK icon
2963
Anika Therapeutics
ANIK
$295M
-7,659
Closed -$274K
ARCO icon
2964
Arcos Dorados Holdings
ARCO
$1.76B
-432,175
Closed -$2.52M
ASPN icon
2965
Aspen Aerogels
ASPN
$505M
-375,968
Closed -$18.7M
ATLC icon
2966
Atlanticus Holdings
ATLC
$1.51B
-4,455
Closed -$318K
AZN icon
2967
CALL
AstraZeneca
AZN
$244B
-4,750
Closed -$524K
BILI icon
2968
Bilibili
BILI
$7.16B
-818,672
Closed -$38M
BLFS icon
2969
BioLife Solutions
BLFS
$1.72B
-5,962
Closed -$222K
BLND icon
2970
Blend Labs
BLND
$338M
-208,218
Closed -$1.53M
CATX icon
2971
Perspective Therapeutics
CATX
$364M
-6,150
Closed -$24K
CLRB icon
2972
Cellectar Biosciences
CLRB
$20.6M
-139
Closed -$28K
CNVS icon
2973
Cineverse
CNVS
$70.8M
-2,005
Closed -$47K
CTRN icon
2974
Citi Trends
CTRN
$631M
-2,214
Closed -$210K
DSGR icon
2975
Distribution Solutions Group
DSGR
$1.61B
-8,438
Closed -$231K

Similar funds

T. Rowe Price Associates's Q1 2022 Portfolio in Review

As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
  • T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
  • T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
  • T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
  • T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
  • T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.